Justin Timothy Sargent, PT DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 172 Town Hill Rd, Louisa, KY 41230 Phone: 606-324-0540 Fax: 606-324-0616 |
Eastern Kentucky Sports And Orthopedic Physical Therapy Psc Physical Therapist Medicare: Medicare Enrolled Practice Location: 205 East Main Street, Louisa, KY 41230 Phone: 606-244-5999 |
Tri State Rehab Services Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 172 Town Hill Rd, Louisa, KY 41230 Phone: 606-638-7848 Fax: 606-638-7849 |
Morgan Dawn Lester, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 205 East Main Street, Louisa, KY 41230 Phone: 606-244-5999 |
News Archive
In a special issue of Immunotherapy, leading experts provide in-depth review of innovative strategies that may further the success of adoptive cell immunotherapy as a cancer treatment. Adoptive cell immunotherapy (ACT) has proven successful in clinical trials against certain types of melanoma and leukemia. The journal reviews new strategies to address the challenges of extending these effects to a wider range of tumor types.
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).
Spinal cord injuries impact more than 17,000 Americans each year, and although those with incomplete injuries may regain control of their limbs, overall muscle strength and mobility is weakened. Neurorehabilitation using robotic exoskeletons or electrical stimulation devices can help a person regain movement through repeated exercise.
Overdose is not the only cause of death among people who die as a result of using the drug methamphetamine or "ice," say researchers.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, announced that it has entered into a definitive securities purchase agreement with a group of select institutional investors to purchase US$10 million of its securities in a registered direct offering. No placement agent was utilized in connection with the offering.
› Verified 8 days ago